Magnetar Financial LLC Purchases Shares of 38,287 STERIS plc $STE

Magnetar Financial LLC purchased a new stake in STERIS plc (NYSE:STE) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 38,287 shares of the medical equipment provider’s stock, valued at approximately $9,197,000.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Allworth Financial LP increased its position in shares of STERIS by 7.3% during the 2nd quarter. Allworth Financial LP now owns 661 shares of the medical equipment provider’s stock worth $159,000 after purchasing an additional 45 shares during the last quarter. Ashton Thomas Private Wealth LLC grew its stake in STERIS by 3.5% in the 1st quarter. Ashton Thomas Private Wealth LLC now owns 1,611 shares of the medical equipment provider’s stock valued at $365,000 after buying an additional 54 shares during the last quarter. Cetera Investment Advisers raised its holdings in STERIS by 0.9% in the 1st quarter. Cetera Investment Advisers now owns 6,999 shares of the medical equipment provider’s stock valued at $1,586,000 after acquiring an additional 63 shares during the period. Horizon Investments LLC lifted its position in STERIS by 4.7% during the first quarter. Horizon Investments LLC now owns 1,410 shares of the medical equipment provider’s stock worth $320,000 after acquiring an additional 63 shares during the last quarter. Finally, Alliance Wealth Advisors LLC UT boosted its holdings in shares of STERIS by 2.0% during the first quarter. Alliance Wealth Advisors LLC UT now owns 3,305 shares of the medical equipment provider’s stock worth $749,000 after acquiring an additional 64 shares during the period. 94.69% of the stock is owned by institutional investors and hedge funds.

STERIS Stock Performance

STERIS stock opened at $257.09 on Friday. The company has a quick ratio of 1.53, a current ratio of 2.22 and a debt-to-equity ratio of 0.27. The stock has a market cap of $25.23 billion, a PE ratio of 39.37 and a beta of 1.02. STERIS plc has a 12-month low of $200.98 and a 12-month high of $268.30. The business’s 50-day moving average price is $246.64 and its two-hundred day moving average price is $241.14.

STERIS (NYSE:STE) last posted its earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.38 by $0.09. STERIS had a net margin of 11.61% and a return on equity of 14.17%. The firm had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.43 billion. During the same quarter in the prior year, the business earned $2.14 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. As a group, analysts expect that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 18th. Investors of record on Tuesday, November 18th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Tuesday, November 18th. This represents a $2.52 annualized dividend and a dividend yield of 1.0%. STERIS’s dividend payout ratio (DPR) is 36.21%.

Insider Buying and Selling

In other news, VP John Adam Zangerle sold 15,000 shares of STERIS stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $265.14, for a total transaction of $3,977,100.00. Following the sale, the vice president directly owned 33,669 shares of the company’s stock, valued at approximately $8,926,998.66. This trade represents a 30.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Renato Tamaro sold 5,036 shares of the business’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $257.55, for a total value of $1,297,021.80. Following the sale, the vice president owned 5,695 shares in the company, valued at approximately $1,466,747.25. This trade represents a 46.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 20,195 shares of company stock worth $5,312,571 in the last 90 days. Insiders own 1.07% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on STE shares. Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 14th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of STERIS in a report on Tuesday, October 14th. Finally, Morgan Stanley increased their target price on STERIS from $276.00 to $295.00 and gave the stock an “overweight” rating in a report on Friday, August 8th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, STERIS currently has an average rating of “Moderate Buy” and an average target price of $273.50.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.